BACKGROUND: The aims of this study were to determine the incidence of tuberculosis (TB) and nontuberculous mycobacteria (NTM) lung disease in patients who were treated with tumor necrosis factor (TNF) antagonists in South Korea and to evaluate their clinical characteristics. METHODS: We surveyed all patients (N = 509) who were treated with TNF antagonists at Severance Hospital, South Korea, between January 2002 and December 2011. We reviewed the patients' medical records and collected microbiological, radiographic, and clinical data, including the type of TNF blocker(s) used and the results of tuberculin skin tests and interferon-gamma release assays. RESULTS: Rheumatoid arthritis (43.6 %) and ankylosing spondylitis (27.9 %) were the most common diseases in the patients treated with TNF antagonists. Patients received etanercept (33.4 %), infliximab (23.4 %), or adalimumab (13.2 %). The remaining patients received two or more TNF antagonists (30 %). Nine patients developed TB, and four patients developed NTM lung disease. After adjustment for age and sex, the standardized TB incidence ratio was 6.4 [95 % CI 3.1-11.7] compared with the general population. The estimated NTM incidence rate was 230.7 per 100,000 patients per year. CONCLUSIONS: Our results show that mycobacterial infections increase in patients treated with TNF antagonists. The identification of additional predictors of TB for the treatment of latent tuberculosis infection and the careful monitoring and timely diagnosis of NTM-related lung disease are needed for patients who receive long-term therapy with TNF antagonists.
BACKGROUND: The aims of this study were to determine the incidence of tuberculosis (TB) and nontuberculous mycobacteria (NTM) lung disease in patients who were treated with tumor necrosis factor (TNF) antagonists in South Korea and to evaluate their clinical characteristics. METHODS: We surveyed all patients (N = 509) who were treated with TNF antagonists at Severance Hospital, South Korea, between January 2002 and December 2011. We reviewed the patients' medical records and collected microbiological, radiographic, and clinical data, including the type of TNF blocker(s) used and the results of tuberculin skin tests and interferon-gamma release assays. RESULTS:Rheumatoid arthritis (43.6 %) and ankylosing spondylitis (27.9 %) were the most common diseases in the patients treated with TNF antagonists. Patients received etanercept (33.4 %), infliximab (23.4 %), or adalimumab (13.2 %). The remaining patients received two or more TNF antagonists (30 %). Nine patients developed TB, and four patients developed NTM lung disease. After adjustment for age and sex, the standardized TB incidence ratio was 6.4 [95 % CI 3.1-11.7] compared with the general population. The estimated NTM incidence rate was 230.7 per 100,000 patients per year. CONCLUSIONS: Our results show that mycobacterial infections increase in patients treated with TNF antagonists. The identification of additional predictors of TB for the treatment of latent tuberculosis infection and the careful monitoring and timely diagnosis of NTM-related lung disease are needed for patients who receive long-term therapy with TNF antagonists.
Authors: P E Lipsky; D M van der Heijde; E W St Clair; D E Furst; F C Breedveld; J R Kalden; J S Smolen; M Weisman; P Emery; M Feldmann; G R Harriman; R N Maini Journal: N Engl J Med Date: 2000-11-30 Impact factor: 91.245
Authors: Hye Won Kim; Jin Kyun Park; Ji-Ae Yang; Young Im Yoon; Eun Young Lee; Yeong Wook Song; Hang Rae Kim; Eun Bong Lee Journal: Clin Rheumatol Date: 2013-09-22 Impact factor: 2.980
Authors: Ja Min Byun; Chang Kyun Lee; Sang Youl Rhee; Hyo-Jong Kim; Jung-Wook Kim; Jae-Jun Shim; Jae Young Jang Journal: J Korean Med Sci Date: 2015-01-21 Impact factor: 2.153
Authors: Chang Hwan Choi; In Do Song; Young Ho Kim; Ja Seol Koo; You Sun Kim; Joo Sung Kim; Nayoung Kim; Eun Soo Kim; Jae Hak Kim; Ji Won Kim; Tae Oh Kim; Hyun Soo Kim; Hyo Jong Kim; Young Sook Park; Dong Il Park; Soo Jung Park; Hyun Joo Song; Sung Jae Shin; Suk Kyun Yang; Byong Duk Ye; Kang Moon Lee; Bo In Lee; Sun Young Lee; Chang Kyun Lee; Jong Pil Im; Byung Ik Jang; Tae Joo Jeon; Yu Kyung Cho; Sae Kyung Chang; Seong Ran Jeon; Sung Ae Jung; Yoon Tae Jeen; Jae Myung Cha; Dong Soo Han; Won Ho Kim Journal: Yonsei Med J Date: 2016-11 Impact factor: 2.759
Authors: Seung Bin Cha; Bo Young Jeon; Woo Sik Kim; Jong-Seok Kim; Hong Min Kim; Kee Woong Kwon; Sang-Nae Cho; Sung Jae Shin; Won-Jung Koh Journal: PLoS One Date: 2015-09-25 Impact factor: 3.240
Authors: Cheng Chen; Tao Zhu; Zhijian Wang; Hong Peng; Wen Kong; Yang Zhou; Yan Shao; Limei Zhu; Wei Lu Journal: PLoS One Date: 2015-10-27 Impact factor: 3.240